JNJ vs ABT
By Alex · Tickerpine
Johnson & Johnson vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABT |
|---|---|---|
| Price | $254.66 | $94.12 |
| Market cap | $613.02B | $163.94B |
| P/E ratio | 29.5 | 26.4 |
| ROE | 26.42% | 12.33% |
| Profit margin | 21.83% | 13.90% |
| Revenue growth | 9.90% | 7.80% |
| Dividend yield | 2.10% | 2.68% |
| Beta | 0.26 | 0.62 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABT in plain English
- JNJ is the bigger company — about 3.7× the market cap of ABT.
- ABT is cheaper on earnings (P/E 26.4 vs 29.5).
- JNJ earns a higher return on equity (26% vs 12%).
- JNJ is growing revenue faster (10% vs 8%).
- ABT has the higher dividend yield (2.68% vs 2.10%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.